CALPACS members and the general community are cordially invited to our Fall Luncheon. This year, we will host Matt Kaller of Amgen for a lecture on a drug discovery. Matt will detail the discovery and development of AMG193, which is currently in clinical trials for the treatment of solid tumors. The event will include appetizers and a three course lunch. Attendees may to attend the annual open session of the CALPACS Executive Committee.
Title: Discovery of AMG193 for the Treatment of MTAP-Deleted Cancers
Date & Time: Saturday, October 4, 2024 at 11:30 – 2:00 PM
Place: Firestone Walker Barrelworks, 620 McMurray Rd, Buellton, CA 93427
Cost: $20/$10 for students
Note: Seating is limited.
Please click here to make your reservation. After paying, you will be asked for your meal preferences. Please fill out that form.
MTAP (S-methyl-5′-thioadenosine phosphorylase)deletion occurs in 10–15% of all human cancers due to its proximity to the tumor suppressor gene CDKN2A. From screening to preclinical models, Matt will detail the discovery of MTA-cooperative PRMT5 inhibitor AMG 193, a molecule that inhibited the proliferation of HCT116 MTAP-deleted cells with ∼40x selectivity over HCT116 MTAP-WT cells. AMG 193 was orally efficacious in mouse xenografts and is currently in Phase I/II clinical trials for the treatment of advanced MTAP-deleted solid tumors.
Matt Kaller received his B.S. in Chemistry from California State University at Fullerton in 1998. He then joined Amgen in 2000 and has contributed to over 15 programs, including 7 programs that progressed to the clinic. Matt has experience in multiple therapeutic areas including neuroscience, cardiometabolic, inflammation, and oncology.